These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 27974628)

  • 21. Top ten hot topics in parenteral science and technology.
    Akers MJ; Nail SL; Saffell-Clemmer W
    PDA J Pharm Sci Technol; 2007; 61(5):337-61. PubMed ID: 18047174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microbiological testing of pharmaceuticals and cosmetics in Egypt.
    Zeitoun H; Kassem M; Raafat D; AbouShlieb H; Fanaki N
    BMC Microbiol; 2015 Dec; 15():275. PubMed ID: 26653032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of different incubation conditions for microbiological environmental monitoring.
    Gordon O; Berchtold M; Staerk A; Roesti D
    PDA J Pharm Sci Technol; 2014; 68(5):394-406. PubMed ID: 25336415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Environmental and Personnel Monitoring Programs-A Risk-Based Case Study of
    Tidswel EC; Boone K
    PDA J Pharm Sci Technol; 2020; 74(4):408-422. PubMed ID: 32060223
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Future supply chains enabled by continuous processing--opportunities and challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Srai JS; Badman C; Krumme M; Futran M; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):840-9. PubMed ID: 25631279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous and Effective Microbiological Air Monitoring in Critical Environments: A Comparison of Analytical Methodologies.
    Dalmaso G; Campanella A; Lazzeri P
    PDA J Pharm Sci Technol; 2020; 74(4):446-455. PubMed ID: 32060221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality Control: microbial limit tests for nonsterile pharmaceuticals, part 2.
    Vu N; Lou JR; Kupiec TC
    Int J Pharm Compd; 2014; 18(4):305-10. PubMed ID: 25474859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D
    J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A preliminary investigation into the ability of three rapid microbiological methods to detect microorganisms in hospital intravenous pharmaceuticals.
    Hiom S; Denyer S; Talbot C; Maillard JY; Spark P; Smith J
    PDA J Pharm Sci Technol; 2013; 67(4):376-86. PubMed ID: 23872446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cleaning Validation: Complete Guide for Health - Based Approach in Chemical Cross - Contamination Risk Assessment.
    Tanyous JN
    PDA J Pharm Sci Technol; 2019; 73(2):204-210. PubMed ID: 30361288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality Assurance and Quality Control, Part 2.
    Akers MJ
    Int J Pharm Compd; 2015; 19(3):215-21. PubMed ID: 26714362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacterial endotoxin requirements for dry powder inhalants and their excipients: are they critical quality attributes?
    Cundell AM
    PDA J Pharm Sci Technol; 2014; 68(5):386-93. PubMed ID: 25336414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Media-fill simulation tests in manual and robotic aseptic preparation of injection solutions in syringes.
    Krämer I; Federici M; Kaiser V; Thiesen J
    J Oncol Pharm Pract; 2016 Apr; 22(2):195-204. PubMed ID: 25549919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Points to Consider: Best Practices to Identify Particle Entry Routes along the Manufacturing Process for Parenteral Formulations.
    Anger S; Begat C; Crnko V; Fantozzi G; Farach W; Fitzpatrick S; Gallagher B; Huelsmann S; Kinsey P; Langlade V; Lefevre G; Legendre E; McLean K; Miller J; Patel R; Perry A; Soukiassian H; Stanton A; Streich D; Timmons C; Vaneylen D; van Hoose T; Wildling L; Windover M
    PDA J Pharm Sci Technol; 2019; 73(6):635-647. PubMed ID: 31420504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk management, cGMP, and the evolution of aseptic processing technology.
    Agalloco J; Akers J; Baseman H; Boeh R; Madsen R; Ostrove S; Pavell A
    PDA J Pharm Sci Technol; 2009; 63(1):8-10. PubMed ID: 19455938
    [No Abstract]   [Full Text] [Related]  

  • 37. Acceptance Probability (P a) Analysis for Process Validation Lifecycle Stages.
    Alsmeyer D; Pazhayattil A; Chen S; Munaretto F; Hye M; Sanghvi P
    AAPS PharmSciTech; 2016 Apr; 17(2):516-22. PubMed ID: 26024723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. End-preparation assessments and tests for compounded sterile preparations.
    McElhiney LF
    Int J Pharm Compd; 2013; 17(4):307-11. PubMed ID: 24261146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microbial identification strategies in the pharmaceutical industry.
    Cundell AM
    PDA J Pharm Sci Technol; 2006; 60(2):111-23. PubMed ID: 16696194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The regulatory framework for preventing cross-contamination of pharmaceutical products: History and considerations for the future.
    Sargent EV; Flueckiger A; Barle EL; Luo W; Molnar LR; Sandhu R; Weideman PA
    Regul Toxicol Pharmacol; 2016 Aug; 79 Suppl 1():S3-S10. PubMed ID: 27230736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.